News
GSK plc has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted the company's regulatory ...
GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...
Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted UK pharma major GSK’s regulatory application to expand the ...
(Alliance News) - GSK PLC on Friday announced that Japan has accepted a regulatory application to expand the use of its respiratory syncytial virus [RSV] vaccine Arexvy.
GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...
Japanese regulators have accepted GSK's application to expand the use of its RSV vaccine, Arexvy, to the entire adult ...
GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older
London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...
Drugmaker GSK said on Friday that its RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines ...
After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...
(Reuters) -The U.S. Centers for Disease Control and Prevention panel of vaccine experts will vote on shots for respiratory ...
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results